- Trials with a EudraCT protocol (31,635)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (16,520)
31,635 result(s) found for: 0.
Displaying page 1,146 of 1,582.
EudraCT Number: 2014-001001-40 | Sponsor Protocol Number: DT-DP-UC-CR-01 | Start Date*: 2014-06-13 |
Sponsor Name:DermaTools Biotech GmbH | ||
Full Title: A multicentre, double-blind, randomised, controlled phase II/III study to evaluate the efficacy and safety of the new wound healing solution Diperoxochloric acid (DPOCl, DermaPro®) in patients with... | ||
Medical condition: Venous leg ulcer (ulcus cruris) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019543-19 | Sponsor Protocol Number: 20090203 | Start Date*: 2010-10-29 | |||||||||||
Sponsor Name:Amgen Limited | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects wth Inadequately Controlled Asthma | |||||||||||||
Medical condition: Asthma: Subjects with chronic inflammatory disorder of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing resulting from abnormal airflow ob... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) HU (Completed) FI (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019825-32 | Sponsor Protocol Number: CRAD001X2201 | Start Date*: 2010-07-28 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis. | |||||||||||||
Medical condition: Lymphangioleiomyomatosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004456-19 | Sponsor Protocol Number: A3L21 | Start Date*: 2012-04-10 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur S.A | ||||||||||||||||||||||||||||
Full Title: Phase III, open-label, multi-center booster vaccination study in toddlers who completed a three-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine or Infanrix hexa™ in Study A3L11. | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004405-41 | Sponsor Protocol Number: CLI-05993BA1-02 | Start Date*: 2018-09-06 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A phase II, multicentre, randomised, double-blind, double-dummy, active-controlled, 3-way cross-over study to evaluate the efficacy of CHF 5993 administered via Dry Powder Inhaler (DPI) versus CHF ... | |||||||||||||
Medical condition: chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) CZ (Completed) BG (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003401-87 | Sponsor Protocol Number: SND103285 | Start Date*: 2006-02-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) BE (Completed) FR (Completed) EE (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005967-25 | Sponsor Protocol Number: BVT.115959-005 | Start Date*: 2007-03-06 |
Sponsor Name:Biovitrum AB | ||
Full Title: A double-blind, placebo-controlled, randomized, parallel-group study evaluating the efficacy and tolerability of oral BVT.115959, a novel A2A agonist, versus placebo in the treatment of diabetic ne... | ||
Medical condition: Diabetic Neuropathic Pain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) GB (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005513-35 | Sponsor Protocol Number: MK-0653A Protocol 809-00 | Start Date*: 2007-02-05 | |||||||||||
Sponsor Name:Laboratoires Merck Sharp & Dohme - Chibret | |||||||||||||
Full Title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in... | |||||||||||||
Medical condition: Adjunctive therapy to diet for the reduction of elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) EE (Completed) LT (Completed) CZ (Completed) PT (Completed) LV (Completed) IT (Completed) GR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000577-29 | Sponsor Protocol Number: S187.3.001 | Start Date*: 2007-04-27 | |||||||||||
Sponsor Name:Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories) | |||||||||||||
Full Title: A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with... | |||||||||||||
Medical condition: Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017663-42 | Sponsor Protocol Number: GIMEMACLL0809 | Start Date*: 2010-11-24 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
Full Title: A Single-Arm Multi-Center Trial of Bendamustine given with Ofatumumab (BendOfa) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
Medical condition: Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005732-27 | Sponsor Protocol Number: UCSC-OM-SU-01 | Start Date*: 2006-12-21 | |||||||||||
Sponsor Name:Policlinico Universitario Agustino Gemelli | |||||||||||||
Full Title: EFFICACY AND SAFETY OF THE MULTITARGET INHIBITOR AGENT SU11248 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA | |||||||||||||
Medical condition: Advanced (localized disease but surgically unresectable or metastatic) histologically/cytologically proven hepatocellular carcinoma (or hepatic lesion and aFP ³ 400 ng/ml). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001590-25 | Sponsor Protocol Number: CC-10004-PSA-006 | Start Date*: 2013-10-03 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) MONOTHERAPY IN SUBJECTS WITH ACTIVE PSORIATI... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003228-19 | Sponsor Protocol Number: EVP-6124-017 | Start Date*: 2014-02-26 | ||||||||||||||||
Sponsor Name:EnVivo Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an ... | ||||||||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Completed) GB (Completed) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005055-17 | Sponsor Protocol Number: MRZ60201_3071_1 | Start Date*: 2013-09-26 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: Open-label, non-controlled, multicenter long-term study to investigate the safety and efficacy of Xeomin® (incobotulinumtoxin A, NT 201) for the treatment of spasticity of the lower limb(s) or of c... | |||||||||||||
Medical condition: Lower limb and combined lower limb and upper limb spasticity due to cerebral palsy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) EE (Completed) SK (Completed) CZ (Completed) Outside EU/EEA FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004434-33 | Sponsor Protocol Number: A3L17 | Start Date*: 2012-04-10 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur S.A | ||||||||||||||||||||||||||||
Full Title: Phase III, randomized, blind-observer, single-center, controlled trial of the DTaP-IPV-Hep B-PRP-T vaccine in 266 healthy Peruvian infants. | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004454-26 | Sponsor Protocol Number: A3L10 | Start Date*: 2012-04-10 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur SA | ||||||||||||||||||||||||||||
Full Title: Mono-center, open-label, randomized, active-controlled trial in 310 infants | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001646-18 | Sponsor Protocol Number: AMB115811 | Start Date*: 2013-04-25 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | |||||||||||||
Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) AT (Completed) DE (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002500-24 | Sponsor Protocol Number: AOSD.2014.001 | Start Date*: 2015-02-19 | |||||||||||
Sponsor Name:AB2 Bio Ltd. | |||||||||||||
Full Title: Open-label, multicenter, dose-escalating phase II study to investigate the safety, tolerability, and early signs of efficacy of subcutaneous administrations of Tadekinig alfa (IL-18BP) in patients ... | |||||||||||||
Medical condition: Adult -onset Still’s Disease (AoSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000727-85 | Sponsor Protocol Number: GS-US-104-0321 | Start Date*: 2015-02-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents | |||||||||||||
Medical condition: Human Immunodeficiency Virus-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002313-22 | Sponsor Protocol Number: ADV6770-A11CS | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:ADVICENNE PHARMA SA | ||||||||||||||||||
Full Title: A randomised, active controlled, open-label, 2-way cross-over, multicentre study to investigate the palatability, acceptability, pharmacokinetics, safety and tolerability, and treatment compliance ... | ||||||||||||||||||
Medical condition: Children with chilhood absence epilepsy. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
